Company: PTPI
Filing Date: 2025-03-07
Form Type: PRE 14A
Source: 0001104659-25-021794
Chunk: 1

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-03-07
Form: PRE 14A
Chunk 1
---
, par value $0.0001 per share
(the “Common Stock”) underlying the Series A warrants (the “Series A Warrants”) and Series B warrants
(the “Series B Warrants” and, together with the Series A Warrants, the “Series Warrants”) issued
by us in a public offering transaction on February 19, 2025 (including shares of Common Stock issuable upon operation of certain
anti-dilutions provisions applicable to such Series Warrants, and shares of Common Stock issuable upon “alternative cashless
exercise” feature in the Series B Warrants); (ii) approve an amendment to our Amended and Restated Certificate of Incorporation,
as amended (the “Charter”), to effect, at the discretion of the Board but prior to the one-year anniversary of the date on
which the reverse stock split is approved by the Company’s stockholders at the Special Meeting, a reverse stock split of all of
the outstanding shares of our Common Stock at a ratio in the range of 1-for-250 to 1-for-500, with such ratio to be determined by the
board of directors of the Company in its discretion and included in a public announcement; (iii) approve the Third Amendment to the
Petros Pharmaceuticals, Inc. Amended and Restated 2020 Omnibus Incentive Compensation Plan, as amended, to increase the total number
of shares of the Company’s Common Stock authorized for issuance under such plan by 1,000,000,000, to a total of 1,002,760,000 shares
of Common Stock; (iv) approve an amendment to the Company’s Charter, to increase the number of our authorized shares of Common
Stock from 250,000,000 shares to 7,000,000,000 shares and to make a corresponding change to the number of authorized shares of capital
stock; and (v) approve a proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, to permit
further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval
of any one or more of the foregoing proposals.

The Board recommends the
approval of each of these five proposals. Such other business will be transacted as may properly come before the Special Meeting.

We hope you will be able
to attend the Special Meeting. Whether you plan to attend the Special Meeting or not, your vote is important. We